The recombinant analogue of chaperonin 10, XToll, targeting TLR4 developed by Cbio Ltd, is now being tested in a phase II clinical trial for RA treatment given by subcutaneous injection. The gene discussed is TLR4; the disease is rheumatoid arthritis.